Security key
74168J101
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 720
- Total 13F value
- $2,656
- Share change
- +73
- SEC-reported price per share
- $3.69
- Number of holders
- 2
- Value change
- +$269
- Number of buys
- 1
- Number of sells
- 1
- Shares outstanding
- 181,672,212
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
2
Top holders
2
PRME full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Prime Medicine, Inc. SEC filings
Prime Medicine, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74168J101
Recent filing periods:
Ownership snapshot
Top reported holders of PRME - Prime Medicine, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GV 2019, L.P.
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 12%
13D/G row: GV 2019, L.P.
Showing 1-6 of 15 holder rows.
Quick read
GV 2019, L.P. leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GV 2019, L.P.'s linked filing trail.
Comparable ownership
Top 5
GV 2019, L.P.
12%
ARCH Venture Fund XII, L.P.
10%
Newpath Partners, L.P.
4.7%
FMR LLC
3.8%
T. Rowe Price Investment Manageme...
3.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GV 2019, L.P. |
13D/G
Alphabet Holdings LLC
|
12%
|
$91,756,239
16,562,498 shares
|
$0 | 30 Sep 2025 |
| ARCH Venture Fund XII, L.P. |
13D/G
Robert Nelsen
|
10%
|
$80,853,607
18,587,036 shares
|
$0 | 07 Aug 2025 |
| Newpath Partners, L.P. |
13D/G
|
4.7%
|
$9,769,086
6,105,679 shares
|
$0 | 31 Dec 2024 |
| FMR LLC |
3/4/5
13D/G
13F
Other* · Company
|
3.8%
from 13D/G
|
$126,699,612
8,462,946 shares
|
— | 24 Oct 2022 |
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
Company
|
3.3%
|
$25,659,383
5,995,183 shares
|
-$13,874,784 | 31 Dec 2025 |
| David R. Liu |
3/4/5
10%+ Owner
|
11%
|
$50,920,145
20,240,945 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
720
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
190
Q2 2026 holders
2
Holder diff
-188
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend